NSE · Healthcare · Drug Manufacturers - Specialty & Generic
EPS came in at 33.95 against a street estimate of 24.68 — a beat of 37.6%.
with an average price target of ₹8,447.00.
CONFIDENT Q1 FY27 beat expectations with 24% profit growth YoY despite solvent cost inflation and geopolitical supply chain disruption. Custom synthesis now 60% of revenue; three major CapEx projects nearing validation completion. Q1 FY27 Geographic exposure stable; West Asia supply chain disruption managed via 3-month rolling inventory buffer strategy. Analysts pressed for quantified validation-to-commercial ramp metrics and CapEx revenue contribution; management cited confidentiality agreements and case-by-case variability, declining numerical specificity. Solvent cost isolation question rebuffed as non-generalizable. Margin trajectory treated as year-on-year, not quarterly. 2026-08-01…
Full summary in the app.
| Document | Date |
|---|---|
| Q1 FY27 earnings call DIVI'S LABORATORIES LIMITED – Q1 FY27 EARNINGS SUMMARY HEADLINE NUMBERS • Consolidated total income: ₹3,144 crores (Q1 FY27) vs ₹2,529 crores (Q1 FY | 2026-08-06 |
| Annual report FY2026 DIVI'S LABORATORIES LIMITED - INVESTOR SUMMARY FY 2025-26 HEADLINE NUMBERS • Total Income: ₹10,894 crores • Profit Before Tax: ₹3,436 crores • Profi | 2026-07-15 |
| Q4 FY26 earnings call DIVI'S LABORATORIES LIMITED – Q4 FY26 EARNINGS SUMMARY HEADLINE NUMBERS • Q4 FY26 Revenue: ₹2,986 crores | Full Year FY26 Revenue: ₹11,067 crores (v | 2026-05-29 |
| Quarterly results · Q4 FY26 DIVI'S LABORATORIES LIMITED – FINANCIAL SUMMARY Year Ended March 31, 2026 --- HEADLINE NUMBERS • Full-year revenue from operations: ₹10,388 crores | 2026-05-25 |
| Q3 FY26 earnings call DIVI'S LABORATORIES LIMITED – Q3FY2026 SUMMARY HEADLINE NUMBERS • Q3FY2026 Consolidated Total Income: ₹2,692 crores vs ₹2,401 crores in Q3FY2025 (+1 | 2026-02-14 |
| Quarterly results · Q3 FY26 DIVI'S LABORATORIES LIMITED – FINANCIAL SUMMARY Results for Q3 & Nine Months Ended December 31, 2025 --- HEADLINE NUMBERS • Q3 FY26 Consolidated To | 2026-02-11 |
| Q2 FY26 earnings call DIVI'S LABORATORIES LIMITED - Q2 FY2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 FY2026 Consolidated Total Income: ₹2,860 crores (17% YoY growth from | 2025-11-12 |
| Quarterly results · Q2 FY26 DIVI'S LABORATORIES LIMITED - FINANCIAL SUMMARY HEADLINE NUMBERS • Q2 FY2026 (Quarter ended Sept 30, 2025) - Standalone: - Revenue from operations | 2025-11-07 |
Readable in the app.
| Action | Detail | Date |
|---|---|---|
| Dividend | ₹30 / share ex-date Jul 24, 2026 | 2026-07-24 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Divi's Laboratories Limited — free to start.
Google PlayApp StoreData updated 2026-09-18.